The relationship between intensification of blood glucose-lowering therapies, health status and quality of life in type 2 diabetes: The Fremantle Diabetes Study Phase II

摘要

AimsTo determine whether therapeutic intensification in type 2 diabetes influences health status and quality of life (QoL). MethodsWe studied 930 participants in the longitudinal observational Fremantle Diabetes Study Phase II (mean age 65.3?years, 53.8% males, median diabetes duration 8.0?years) with valid data from baseline assessment and two biennial reviews (4?years of follow-up) between 2008 and 2015. The main outcome measures were the Short Form-12 version 2 physical and mental health composite scores (PCS, MCS) and the average weighted impact (AWI) score from the Audit of Diabetes Dependent QoL. ResultsThere were reductions in PCS at Year 4 compared with baseline and Year 2 in patients on stable diet-based management (n?=?160), oral glucose-lowering medication (OGLM; n?=?387), and insulin with/without OGLM (n?=?168;P?